BACKGROUND: The need for an approach to measuring health results that incorporates patients' and payers' perspectives has generated a wide range of health care outcomes (HCOs), but it is yet unknown whether these HCOs are appropriate or valid for the health care decision-making process. OBJECTIVE: The goal of this study was to assess HCOs, patient-reported outcomes (PROs), and economic outcomes in terms of validity and appropriateness to health care decision making in type 2 diabetes mellitus (T2DM). METHODS: This systematic review of studies published between January 1, 1996, and November 1, 2010, comprised an electronic literature search of MEDLINE and Centre for Reviews and Dissemination databases. Studies included were clinical trials, observational studies, economic analyses, and studies on the development and validation of HCOs in T2DM in the adult population. HCOs were assessed and classified according to their relevance for decision makers in terms of feasibility for routine use, validity, sensitivity, reliability, understanding, and scope. RESULTS: Two independent reviewers screened 4497 citations. Of these, 281 potentially eligible full articles were retrieved, and 185 met the inclusion criteria. A total of 121 HCOs in T2DM were identified: 80 (66.1%) PROs and 41 (33.9%) economic outcomes. Only 44.6% of the outcomes assessed were appropriate and valid for health care decision making. Greater deficiencies in evidence were found for PROs (61.3%), followed by economic outcomes (43.9%). CONCLUSIONS: A large number of HCOs are being used in the health care decision-making process, but a significant proportion of these new outcomes have not been properly validated. Despite the fact that appropriate measures will depend on the specific needs of the decision makers, researchers need to use HCOs for which evidence of quality and appropriateness is available.
BACKGROUND: The need for an approach to measuring health results that incorporates patients' and payers' perspectives has generated a wide range of health care outcomes (HCOs), but it is yet unknown whether these HCOs are appropriate or valid for the health care decision-making process. OBJECTIVE: The goal of this study was to assess HCOs, patient-reported outcomes (PROs), and economic outcomes in terms of validity and appropriateness to health care decision making in type 2 diabetes mellitus (T2DM). METHODS: This systematic review of studies published between January 1, 1996, and November 1, 2010, comprised an electronic literature search of MEDLINE and Centre for Reviews and Dissemination databases. Studies included were clinical trials, observational studies, economic analyses, and studies on the development and validation of HCOs in T2DM in the adult population. HCOs were assessed and classified according to their relevance for decision makers in terms of feasibility for routine use, validity, sensitivity, reliability, understanding, and scope. RESULTS: Two independent reviewers screened 4497 citations. Of these, 281 potentially eligible full articles were retrieved, and 185 met the inclusion criteria. A total of 121 HCOs in T2DM were identified: 80 (66.1%) PROs and 41 (33.9%) economic outcomes. Only 44.6% of the outcomes assessed were appropriate and valid for health care decision making. Greater deficiencies in evidence were found for PROs (61.3%), followed by economic outcomes (43.9%). CONCLUSIONS: A large number of HCOs are being used in the health care decision-making process, but a significant proportion of these new outcomes have not been properly validated. Despite the fact that appropriate measures will depend on the specific needs of the decision makers, researchers need to use HCOs for which evidence of quality and appropriateness is available.
Authors: Ellen B M Elsman; Lidwine B Mokkink; Marlous Langendoen-Gort; Femke Rutters; Joline Beulens; Petra J M Elders; Caroline B Terwee Journal: BMJ Open Diabetes Res Care Date: 2022-06
Authors: José A Sacristán; Alfonso Aguarón; Cristina Avendaño-Solá; Pilar Garrido; Juan Carrión; Alipio Gutiérrez; Robert Kroes; Angeles Flores Journal: Patient Prefer Adherence Date: 2016-04-27 Impact factor: 2.711
Authors: Ava S Runge; Lynn Kennedy; Adam S Brown; Abigail E Dove; Brian J Levine; Sophie P Koontz; Varun S Iyengar; Sarah A Odeh; Kelly L Close; Irl B Hirsch; Richard Wood Journal: Clin Diabetes Date: 2018-04
Authors: Christoffer Bartz-Johannessen; Ove Furnes; Anne Marie Fenstad; Stein Atle Lie; Alma Becic Pedersen; Søren Overgaard; Johan Kärrholm; Henrik Malchau; Keijo Mäkelä; Antti Eskelinen; Jeremy M Wilkinson Journal: Clin Epidemiol Date: 2019-07-10 Impact factor: 4.790
Authors: Caroline B Terwee; Petra J M Elders; Marlous Langendoen-Gort; Ellen B M Elsman; Cecilia A C Prinsen; Amber A van der Heijden; Maartje de Wit; Joline W J Beulens; Lidwine B Mokkink; Femke Rutters Journal: Curr Diab Rep Date: 2022-07-11 Impact factor: 5.430
Authors: Josep Franch-Nadal; Elena Labrador Barba; M Carmen Gómez-García; Pilar Buil-Cosiales; José Manuel Millaruelo; María Luisa Orera Peña Journal: Patient Prefer Adherence Date: 2015-10-08 Impact factor: 2.711